TSO₃ exhibits 125L Ozone Sterilizer at AORN in San Diego

March 23, 2004

Québec City, March 23, 2004 – TSO3 Inc. (“TSO3”) and its distribution partner Skytron, exhibit the 125L Ozone Sterilizer at AORN’s (Association of Registered Nurses) 51st Congress held in San Diego, California, from March 23 to March 25, 2004.  More than 13,000 international Peri-Operative Nurses and participants attend the AORN congress annually. Their goal is to learn about recent advances in medical innovation and continuous improvement in healthcare practices.

AORN reports that: 86% visit exhibit booths to keep up to date and to obtain information for purchasing; 40% use information gathered on the Exhibit floor to make purchases after Congress; 84% are decision makers or influence decisions about the purchase of products and/or equipment and of these decision-making members, 56% have increased their purchasing influence at work.

“This convention is a ‘must’ for hospitals which are planning facility and process improvements that will enhance patient care. TSO3 is privileged to present its 125L sterilizer as part of the Skytron exhibit.  Skytron is one of the largest vendors at the Congress, and the prominent size of its exhibit will encourage booth traffic that will rival other major multinational medical equipment suppliers. TSO3 and Skytron anticipate numerous leads and customers inquiries that will permit us to accelerate the deployment of our referral site program”, stated Jocelyn Vézina, CEO at TSO3 Inc.

AORN is the global leader in promoting excellence in Peri-Operative nursing practice supporting registered nurses in achieving optimal outcomes for patients undergoing operative and other invasive procedures. The association is composed of approximately 40,000 Peri-Operative registered nurses in the United States and abroad. Peri-Operative nurses are defined as "those who provide, manage, teach, and study the care of patients undergoing operative or other invasive procedures."

About AORN

AORN was formally organized between 1949 and 1954. A group of OR supervisors in the New York City area met on January 28, 1949 and voted unanimously for formation. The first national conference was held in 1954. The organization was formally incorporated as AORN, Inc, in 1960. The Headquarters office was relocated to Denver in 1969.AORN currently employs approximately 110 people and teams include Finance and Business Development; Sales and Business Support; Marketing and External Relations; Association and Professional Services; and AORN Foundation.

AORN is a visionary force in the nursing community. It is a highly respected nursing organization that contributes to the welfare of Peri-Operative patients worldwide.

For more information on AORN, visit the association’s Web Site at: http://www.aorn.org 

About TSO3

TSO3 Inc. is located in Québec City (Québec, Canada) and was founded in 1998. TSO3 currently has 43 employees, 16 of whom work exclusively in the Research and Development Department. The company’s mission is to develop and market innovative and comprehensive sterilization solutions.

TSO3 has perfected a novel sterilization process using ozone as a sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize the new generation of surgical and diagnostic instruments made of non-heat-resistant materials such as polymers and plastics. The ozone sterilization process is a safe, efficient, fast and cost-effective response to evolving sterilization needs.

The 125L Ozone Sterilizer was licensed by Health Canada in May 2002 and TSO3 was granted U.S. Food and Drug Administration (FDA) approval September 3, 2003.

The Company’s R&D team has also undertaken the development of a smaller, point-of-use ozone sterilization device for operating rooms and private clinics, and is planning the development of an industrial-sized device for manufacturers of medical instruments, among others.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3 are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -